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ABSTRACT
The ERK/MAP kinase pathway is an important regulator of gene expression and differentiation in postmitotic cells. To understand how
this pathway controls gene expression in bone, we examined the subnuclear localization of P-ERK in differentiating osteoblasts.
Induction of differentiation was accompanied by increased ERK phosphorylation and expression of osteoblast-related genes, including
osteocalcin (Bglap2) and bone sialoprotein (Ibsp). Confocal immunofluorescence microscopy revealed that P-ERK colocalized with the
RUNX2 transcription factor in the nuclei of differentiating cells. Interestingly, a portion of this nuclear P-ERK was directly bound to the
proximal promoter regions of Bglap2 and Ibsp. Furthermore, the level of P-ERK binding to chromatin increased with differentiation,
whereas RUNX2 binding remained relatively constant. The P-ERK-chromatin interaction was seen only in RUNX2-positive cells, required
intact RUNX2-selective enhancer sequences, and was blocked with MAPK inhibition. These studies show for the first time that RUNX2
specifically targets P-ERK to the chromatin of osteoblast-related genes, where it may phosphorylate multiple substrates, including
RUNX2, resulting in altered chromatin structure and gene expression.  2010 American Society for Bone and Mineral Research.
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Introduction
T
he extracellular signal-regulated kinase (ERK)–MAPK and
related signal-transduction pathways have important func-
tions in the differentiation of postmitotic cells beginning in the
earliest stages of development. For example, FGF4 activation of
ERK1/2 is required for embryonic stem (ES) cells to undergo
neural or mesodermal differentiation; genetic deletion of Erk2
completely blocks the FGF4 response, locking cells in a
proliferative state where pluripotency markers continue to be
expressed.
(1) Consistent with this finding, Erk2-null mice exhibit
severe defects in primary mesenchyme formation without major
changes in cell proliferation or apoptosis.
(2) MAP kinase–related
pathways also control gene expression and cellular fate of more
differentiated cells such as mesenchymal stem cells (MSCs) or
osteoprogenitor cells in response to changes in hormone/
growth factor signaling, extracellular matrix (ECM)–integrin
binding, or mechanical environment.
(3–10) Furthermore, the
activity of individual lineage-specific transcription factors such as
MYOD (muscle), SOX9 (cartilage), PPARg (adipose tissue), and
RUNX2 (osteoblasts and hypertrophic chondrocytes) are all
regulated by MAP kinases.
(11–14) Taken together, these studies
indicate that MAP kinases can have global effects on the
differentiation fate of cells during organogenesis.
Using a transgenic approach, we recently established an
important role for ERK-MAPK signaling in skeletal develop-
ment.
(15) Mice overexpressing a constitutively active form of the
MAP kinase intermediate MEK1 in osteoblasts (Mek-sp mice)
exhibited accelerated skeletal development, whereas a domi-
nant-negative MEK1 (Mek-dn mice) inhibited this process.
Similarly, osteoblast-specific gene expression and mineralization
were accelerated in calvarial or marrow cells cultured from Mek-
sp mice, whereas these events were delayed in Mek-dn cells.
Effects of MAP kinase on differentiation appeared to be
mediated by the RUNX2 transcription factor in that constitutively
active MEK1 was able to partially rescue the cleidocranial
dysplasia phenotype associated with Runx2 haploinsufficiency.
These studies provided in vivo validation for previous cell culture
work showing that the ERK-MAP kinase pathway is required for
extracellular matrix (ECM)–induced osteoblast differentiation
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154and that this pathway can stimulate RUNX2 phosphorylation and
transcriptional activity.
(4,13,16,17)
Although the ERK/MAPK pathway has been studied exten-
sively in bone, the subcellular and subnuclear distribution of
activated ERK during osteoblast differentiation has not been
examined previously. The classic view of MAP kinase action
supposes that phosphorylation events are distinct from changes
in gene expression. However, more recent studies indicate that
nuclearkinasesmayinteractdirectlywiththechromatinoftarget
genes to control differentiation fate in response to environ-
mental signals.
(18,19) In this study, we explore this possibility in
bone by examining the intranuclear localization of the terminal
MAP kinase ERK1 in differentiating osteoblasts. As will be shown,
the MAP kinase pathway is activated in response to ECM signals,
resulting in accumulation of P-ERK in the nucleus, where,
together with RUNX2, it specifically associates with osteocalcin
(Bglap2) and bone sialoprotein (Ibsp) genes to induce osteoblast-
specific gene expression.
Materials and Methods
Cell culture
Subclone 4 MC3T3-E1 (MC3T3-E1c4) cells were plated at a
density of 50,000 cells/cm
2 and maintained in growth medium
containing a-Minimal Essential Medium (a-MEM; Life Technol-
ogies, Inc., Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (FBS; Hyclone Laboratories, Logan, UT, USA) and
1% penicillin/streptomycin, as described previously.
(20) To
induce differentiation, cells were cultured in the same medium
containing 50 mg/ml ascorbic acid [differentiation medium
(DM)]. For mineralization studies, DM was supplemented with
5m Mb-glycerol phosphate, and mineral was stained by the von
Kossa method.
(21) Mineralized nodules were photographed
using a Nikon TS100 inverted microscope.
Quantitation of mRNA
Total RNAwas isolatedfrom cells usingTRIzolreagent (Invitrogen)
and cleaned with an RNeasy MiniKit (Qiagen). Two micrograms of
total RNA was reverse transcribed using Taqman reverse
transcriptase (Applied Biosystems) for first-strand synthesis.
Quantitive real-time polymerase chain reaction (PCR) measure-
ment of Ocn, Bsp, and GAPDH mRNA sequences was carried out,
as described previously,
(22) using predeveloped Taqman probes
and an ABI PRISM 7700 sequence detector (Applied Biosystems).
The real-time PCR product, mRNA expression, was calculated
based on a relative standard curve and normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Western blot measurement of Runx2 and MAP kinase
Cells were harvested in lysis buffer (10 Mm Tris, 5 mM EDTA,
0.25% Triton X-100, 150 mM NaCI, PMSF, 1 proteinase inhibitor
cocktail, Sigma). The crude membrane/nuclear fraction was
isolated by centrifugation (10 minutes, 15,000 g) and frac-
tioned by SDS-PAGE using 6% to 20% TG gels. After transfer to
nitrocellulose membranes, samples were incubated with RUNX2
antibody (1:500 dilution; Applied Biosystems) or P-ERK antibody
(1:500 dillution; Cell Signaling) overnight at 48C. A second
antibody of sheep antimouse or donkey antirabbit conjugated
with horseradish perioxidse (GE Healthcare, UK) was used at
1:10000 dilution. Protein expression was detected by ECL
(Amersham).
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were carried out as described previously.
(23) Briefly,
cells were cross-linked with 1% p-formaldehyde for 10 minutes at
room temperature. Chromatin then was isolated and sheared by
sonication to produce an average fragment size of 300 to 500 bp.
Chromatin (10 mg DNA/assay) was precleared by incubation with
protein A/G agarose beads (Santa-Cruz Biotechnology) for 1 hour,
incubated with primary antibodies to Runx2 or P-ERK, and
precipitated with A/G agarose beads. Input DNA and DNA from
ChIP samples were measured by PCR (35 cycles) or by quantitive
real-time PCR using Taqman probes flanking OSE2a, OSE2b, or
control regions in the mOG2 gene, as described previously.
(23) All
PCR primer sequences used in this study to measure interactions
with Bglap2 were described in Roca et al.,
(23) whereas primers for
Ibsp were described in Roca et al.
(24) ChIP assays conducted using
transfected wild-type and mutant 0.6mOG2-Luc plasmid used the
following PCR primers: OSE2a 5’ primer: 5’-CCTTGCCCAGG-
CAGCTGCAATCA-3’; OSE2a 3’ primer: 5’-TCTTCCAGCGGATA-
GAATGGCGC-3’;O S E 2 b5 ’ primer: 5’-CTAGCAAAATAGGCTGT-
CCCCAG-3’; and OSE2b 3’ primer: 5’-GCCTCCATAAGATC-
CGGTTGGTA-3’.ChIP-Re-ChIPanalysiswasconductedasdescribed
by Young et al.
(25) Briefly, chromatin immunocomplexes initially
isolatedwithanti-Runx2antibodyweredisruptedwith10mMDTT
at 378C for30 minutesand then dilutedwith IP buffer. The diluted
chromatin complexes were subjected to the second ChIP analysis
with antibody against P-ERK.
Immunofluorescence localization of Runx2 and P-ERK
MC3T3-E1c4 cells were grown on glass cover slips, fixed with 4%
formaldehyde, and incubated overnight at 48C with primary
antibodies to Runx2 and P-ERK (1:100 dilution). Alexa Fluor 488
conjugated donkey antimouse and Alexa Fluor 555 conjugated
donkey antirabbit (Invitrogen) antibodies were used to visualize
the localization of Runx2 and P-ERK. Fluorescence detection was
accomplished using an Olympus FluoView 500 laser scanning
confocal microscope system with a 100  oil-immersion objec-
tive at room temperature (Microscopy and Image Analysis
Laboratory, University of Michigan School of Medicine).
Transient transfections and luciferase reporter assays
Luciferase reporter plasmids containing 610 bp of mOG2
promoter (0.6mOG2-Luc) with or without mutations in OSE2a
and/orOSE2bsequencesweredescribedpreviously.
(26)Transient
transfection of MC3T3-E1c4 cells was accomplished using
lipofectamine reagent (Invitrogen), and luciferse activity was
measured using a Monolight A200 luminometer. Runx2 expres-
sion in C3H10T1/2 cells was accomplished using a previously
described adenovirus expression vector.
(27)
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The results are presented as mean SE, with n¼3 per group for
all comparisons. Statistical analysis was determined using a one-
way ANOVA followed by Tukey’s multiple-comparison test.
Results
MAP kinase signaling increases during ECM-induced
osteoblast differentiation
Previous work established a requirement for ERK–MAP kinase
signaling in osteoblast differentiation in vitroandinvivo.
(4,13,15) To
examine the temporal relationship between MAP kinase activa-
tion and differentiation, MC3T3-E1c4 cells were cultivated in
growth (GM) or differentiation medium (DM), and the time course
of differentiation marker induction (extracellular matrix miner-
alization, Bglap and Ibspgeneexpression) wascompared withERK
phosphorylation (Fig. 1). DM, which contains ascorbic acid,
stimulates secretion of a collagenous extracellular matrix that
induces osteoblast differentiation by interacting with a2b1
integrins to stimulate ERK-MAPK signaling.
(4,16,28) As expected,
all three differentiation markers were induced after 3 to 6 days in
DM and continued to increase at later time points (panels A–C).
Similarly, P-ERK was detected in the crude nuclear/membrane
fraction of cells after 3 days in DM and subsequent time points
(panel D),whereastotalERK levels remained relativelyconstant.In
contrast, cells maintained in GM did not mineralize, expressed
onlytraceamountsofBglaporIbspmRNA,andhadverylowlevels
of P-ERK. RUNX2 protein levels also were measured on Western
blots (Fig. 1D). Although growth in DM dramatically increased
expression of RUNX2 target genes, levels of RUNX2 protein were
similar in GM- and DM-treated samples at each time point, as
w o u l db ee x p e c t e di fE C M –MAP kinase signals were increasing
RUNX2 transcriptional activity rather than amount.
Differentiation-dependent accumulation of
phosphorylated ERK in the nucleus and colocalization
with RUNX2
Immunofluorescence laser confocal microscopy was used to
examine the intracellular location of P-ERK and RUNX2 during
osteoblast differentiation (Fig. 2). Cells were grown in GM or DM
and stained with specific anti-RUNX2 and anti-P-ERK antibodies
or with DAPI to visualize nuclei. Low-power fields of cell cultures
are shown in Fig. 2A, whereas higher magnifications of single
cells are shown in Fig. 2B. Consistent with the Western blot
results in Fig. 1, RUNX2 immunofluorescence increased gradually
with time regardless of whether cells were cultured in GM or DM,
but in all cases staining was exclusively nuclear. At each time
point, all nuclei stained positively for RUNX2. Fluorescence
intensity increased gradually from 4.5 0.2 10
3 pixels/nucleus
at the beginning of the experiment to 10.6 0.5 10
3 pixels/
nucleus at day 9 (n¼20 nuclei/time point). In contrast, the weak
P-ERK immunofluorence seen in GM cultures was mainly in the
cytosol, although some weak nuclear or perinuclear staining and
colocalization with RUNX2 was seen occasionally. Growth in DM
dramatically changed the distribution of P-ERK from the
cytoplasm to the nucleus at all time points examined. Much
of this nuclear P-ERK colocalized with RUNX2. Although some
heterogeneity in P-ERK and, to a lesser extent, RUNX2
fluorescence was observed, generally, cells that exhibited strong
nuclear P-ERK staining also showed strong colocalization of P-
ERK with RUNX2. Another feature of P-ERK and RUNX2 nuclear
distribution apparent in higher-power views is the punctate
distribution of bothantibodies. This hasbeen proposed toreflect
the localization of proteins to specific subnuclear domains.
(29)
P-ERK binds to specific regions of mouse osteocalcin
gene 2 (Bglap2) chromatin
To more precisely define the nuclear location of P-ERK in
differentiating osteoblasts, we used ChIP analysis to test the
hypothesis that this kinase associates with specific regions of
osteoblast-related genes. This model is based on work in other
Fig. 1. TimecourseofdifferentiationandMAPkinaseactivationinMC3T3-
E1 clone 4 preosteoblast cells. (A–D) Differentiation. Cells were cultured in
growthordifferentiationmedium(þDM)forthetimesindicatedandeither
stained for mineral (A) or analyzed for changes in expression of Bglap2 (B)
or Ibsp genes (C). To assess mineralization, DM was supplemented with
b-glycerol phosphate. Cells were stained by the von Kossa method and
photographed using phase-contract microscopy (bar, 100 mm). For gene
expression analysis, total RNA was isolated, and relative levels of Bglap2
and Ibsp mRNA were measured by Q-RT-PCR. (D) Runx2 and phospho-ERK
expression during osteoblast differentiation. The membrane/nuclear frac-
tions of cell lysates were isolated at the times indicated and extracted into
RIPA buffer for Western blot analysis of RUNX2, phospho-ERK, and total
ERK. Significantly different from corresponding time-matched GM control,
p<.01(
 ).
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kinases can bind to chromatin near tissue-specific transcription
factors such as myoD.
(18)
Our intial studies analyzed interactions between P-ERK and
Bglap2 chromatin. The proximal promoter of this gene, shown
schematically in Fig. 3A, contains two RUNX2 binding sites
designated OSE2a and OSE2b at –130 and –605 bp upstream
from the transcription start site, respectively. Both sites are
necessary for the osteoblast-specific expression of this gene in
vivo.
(26) For ChIP analysis, primers were designed to individually
detect immunoprecipitated chromatin containing OSE2a and
OSEb regions as well as chromatin from a transcribed region
(TSR) 400 bp downstream from OSE2a, which serves as a
negative control. Previous work showed that OSE2a and OSE2b
are sufficiently far apart (469 bp) to not be precipitated in the
same chromatin fragment during ChIP analysis and can,
therefore, be analyzed separately.
(23) MC3T3-E1c4 cells were
cultured in GM or DM, and ChIP analysis was performed using
antibodies specific to RUNX2, P-ERK, or isotype-specific IgG (see
Fig. 3B, C). Panel B shows representative PCR reactions of
samples, whereas panel C quantifies relative amounts of ChIP
DNA using real-time PCR. RUNX2 bound OSE2a and OSE2b
chromatin to a similar degree, and the amount of binding was
modestly increased by differentiation (maximum variation
between GM and DM at 3 and 6 days was two- to threefold).
Interestingly, P-ERK also bound to OSE2a and OSE2b, and this
chromatin binding was strongly upregulated (five- to sixfold) by
growth in DM for 3 or 6 days. However, we did not detect DM-
dependent increases in P-ERK or RUNX2 binding at the 9-day
time point. This is to be contrasted with immunofluorescence
data showing nuclear accumulation of P-ERK and increased
RUNX2 staining intensity at this time. The specificity of these
interactions was confirmed in several ways (panel B): (1) Little or
no PCR signal was obtained when ChIP DNA samples were
analyzed using PCR primers specific to the downstream
transcribed region of Bglap2 (TSR). (2) No ChIP PCR product
was obtained when chromatin was precipitated with control IgG.
In this latter case, we used real-time PCR to detect any residual
OSE2a and OSE2b sequences in IgG immunoprecipitates and
found levels to be consistently below 0.0004 percent of input
(not depicted). (3) P-ERK ChIP DNA samples did not contain
detectable promoter sequences from the Gapdh gene, which is
constitutively active in osteoblasts, indicating that P-ERK
preferentially binds to Bglap2 chromatin and does not generally
associate with the promoter regions of transcribed genes (not
depicted).
As shown in Fig. 3D, binding of P-ERK to Bglap2 chromatin
requires MAP kinase signaling. In this experiment, cells were
grown for 6 days in GM or DM and then treated for 12 hours with
or without the ERK–MAP kinase inhibitor, U0126, which is known
to block Bglap2 and Ibsp expression in MC3T3E1c4 cells.
(4) The
DM-treated group showed increased binding of P-ERK to OSE2a
and OSE2b regions, as expected, and this response was
completely blocked by U0126. In contrast, RUNX2 binding was
not affected by inhibitor treatment. Results of this experiment
were confirmed by real-time PCR of ChIP DNA samples using
primers to the OSE2a region. Percent input values were as
follows: 0-day control: 0.012 0.006; 6-day control: 0.011 
0.002; 6-day DM: 0.036 0.002; 6-day control þ U0126: 0.0094 
0.001; 6-day DM þ U0126: 0.010 0.0055.
Recruitment of P-ERK to Bglap2 chromatin requires
intact OSE2 and RUNX2
The above-described results show that P-ERK selectively binds to
Bglap2 chromatin near the RUNX2-specific enhancers OSE2a and
OSE2b. In view of our previous work showing that ERK–MAP
Fig. 2. Colocalization of P-ERK and RUNX2 in osteoblast cells. MC3T3-E1
clone 4 cells were cultivated in GM or DM for the times indicated. After
fixation, cells were incubated with DAPI, anti-RUNX2, and anti-P-ERK
antibodies, followed by antimouse IgG conjugated with Fluo-Alex 488
and antirabbit IgG conjugated with Fluo-Alex 555. Colocalization was
assessed by confocal microscopy. Merged pseudocolor images are
shown in the indicated panels. Merge1 shows RUNX2 and P-ERK colo-
calization; merge2 combines merge1 with DAPI; DIC, differential inter-
ference contrast. (A) Lower-magnification view showing several cells/
field. Scale bar, 20 mm. (B) Higher magnification showing subcellular
localization in a single cell. Scale bar, 5 mm.
CHROMATIN LOCALIZATION OF MAP KINASE IN BONE Journal of Bone and Mineral Research 157Fig. 3. Association of RUNX2 and P-ERK with OSE2 elements in mOG2 chromatin during osteoblast differentiation. (A) Schematic of the proximal mOG2
promoter showing the location of PCR primer pairs for ChIP assays. Primer pairs P1/P2 and P3/P4 flank OSE2a and OSE2b regions, respectively, whereas
pair P5/P6 amplifies DNA in the transcribed region (TSR) 413 bp downstream from primer P1. (B) ChIP analysis. MC3T3-E1 cells were grown under the
conditions described in Fig. 1, and chromatin was isolatedat the times indicated. Monoclonal anti-RUNX2, anti-P-ERK antibodies, or control IgG were used
to immunoprecipitate chromatin, and ChIP DNA was analyzed by PCR using the primers indicated. (C) Quantitation of ChIP DNA by Q-PCR. Values are
expressed as percent of input DNA. Note the preferential increase in P-ERK associated with OSE2a and OSE2b regions in cells grown in DM and lesser
variation in bound Runx2. Significantly different from corresponding time-matched GM control, p<.01(
 ). (D) MAP kinase inhibition blocks P-Erk, but not
Runx2bindingtoOSE2-containingchromatin.CellsweregrowninGMorDMfor6daysfollowedbytreatmentforanadditional12hoursinthepresenceor
absence of the MAPK inhibitor, U0126. Chromatin then was isolated for ChIP analysis as in panel B.
158 Journal of Bone and Mineral Research LI ET AL.kinase stimulates osteoblast-specific gene expression via a
RUNX2-dependent pathway,
(4,15) we designed a set of experi-
ments to resolve whether the binding of P-ERK to Bglap2 is, in
fact, OSE2- and RUNX2-dependent (Fig. 4).
The first study resolved whether intact OSE2 sequences are
required for P-ERK binding. Cells were transfected with wild-type
0.6mOG2-Luc (contains 0.6 kb of the Bglap2 promoter driving
firefly luciferase) or the same vector containing mutations in
OSE2a, OSE2b, or both sites. In agreement with previous
work,
(26,30) activity of this reporter is strongly induced by growth
in DM for 5 days and highly dependent on intact OSE2a and
OSE2b sequences (panel A). ChIP assays next were used to
determineifOSE2aandOSE2barenecessaryforbindingofP-ERK
to Bglap2. Although ChIP is used most often to examine
chromatin interactions in the context of chromosomal DNA, it
also can be used to examine interactions with transfected
plasmid DNAs. This is possible because transfected DNA is
assembled into nucleosomes resembling the normal chromatin
structure.
(31) For this experiment, specific PCR primers were
designed to detect interactions with the 0.6mOG2-Luc plasmid
without interference from the endogenous Bglap2 gene (see
Fig. 4B). To detect interactions with OSE2a, a 5’ primer was
designed complementary to sequences upstream of the OSE2a
region, and a 3’ primer was selected in the luciferase coding
region. To detect OSE2b binding, the 5’ primer was in the pGL3
plasmid sequence, and the 3’ primer was slightly downstream of
OSE2b. The results of ChIP assays are shown in panel C. Binding
of both RUNX2 and P-ERK to both OSE2a and OSE2b regions of
the wild-type 0.6mOG2-Luc plasmid was easily detected. In
contrast, mutation of OSE2a reduced RUNX2 and P-ERK binding
Fig. 4. Association of P-ERK with mOG2 chromatin requires intact OSE2 regions and RUNX2. (A) Effect of OSE2 mutations on mOG2 promoter activity. To
confirm that OSE2a and OSE2b are required for activation of Ocn, MC3T3-E1c4 cells were transfected with wild-type 0.6mOG2-luc (wt) or 0.6mOG2-luc
harboring point mutations in OSE2a (–a), OSE2b (–b), or both sites (–a/b) and assayed for luciferase activity after growth in GM or DM for 6 days. The OSE2
mutant is significantly different from wild- type (DM samples only), p<.01(
 ). (B) Schematic showing location of PCR primers used for detecting
interactions with OSE2a or OSE2b in WT or mutant 0.6mOG2-luc. (C) Mutation of OSE2 sites block binding of RUNX2 and P-ERK to mOG2 chromatin. Cells
were transfected with WT or mutant 0.6mOG2-luc and cultured in GM or DM as in panel A. Isolated chromatin fragments were precipitated with anti-
RUNX2 and anti-P-ERK antibodies or control IgG and ChIP DNA analyzed by PCR using the primers indicated. (D) Runx2 is indispensable for binding of P-
ERK to mOG2chromatin.C3H10T1/2mesenchymal cellswere transducedwith control adenovirus (AdLacZ)or an adenovirusexpressing Runx2(AdRunx2)
and grown for 4 days before chromatin isolation and ChIP analysis. Note the lack of a positive ChIP signal for P-ERK in the absence of RUNX2. (E) ChIP-re-
ChIP detection of RUNX2 and P-ERK on Bglap2 chromatin. MC3T3-E1c4 cells were grown for 6 days as in panel A. ChIP was performed using anti-RUNX2
antibody. A portion of the immunoprecipitated chromatin complex was eluted from agarose beads and subjectedto a second ChIP with either anti-P-ERK
antibody or IgG. ChIP DNA then was analyzed using PCR primers specific to OSE2a and OSE2b (see Fig. 1A).
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of OSE2b was without effect. Similarly, mutation of OSE2b
reduced binding of both proteins, as measured using the OSE2b
primers, whereas the OSE2a mutation did not affect binding.
Finally, mutation of both sites reduced ChIP signals detected by
either primer pair. From these studies we conclude that binding
of P-ERK to Bglap2 chromatin requires intact RUNX2 binding
sites.
To examine the requirement for RUNX2 in this response, ChIP
analyis was conducted using C3H10T1/2 mesenchymal cells with
or without transduction with a RUNX2-expressing adenovirus
(ses Fig. 4D). These cells normally express very low levels of
RUNX2,
(27) and as can be seen, no RUNX2 or P-ERK was detected
in complex with OSE2a or OSE2b when cells were transduced
with a control AdLacZ virus. In contrast, AdRunx2 transduction
led to positive ChIP reactions for both RUNX2 and P-ERK.
Final confirmation that RUNX2 and P-ERK reside on the same
chromatin fragment came from ChIP/re-ChIP analysis (see
Fig. 4E). For this experiment, MC3T3E1c4 cells were grown in
DMfor6days.ChIPwascarriedoutinitiallywithRUNX2antibody.
Theimmunoprecipitatethenwasspitintothirds.Thefirstportion
was used for PCR analysis of precipitated DNA (RUNX2), the
second was resuspended and precipitated with anti-P-ERK
(RUNX2þP-ERK), and the third was precipitated with IgG. As can
be seen, the anti-RUNX2 immunoprecipitate was specifically
reprecipitated with the P-ERK antibody.
Binding of P-ERK and RUNX2 to the bone sialoprotein
gene (Ibsp)
Ibsp is a second major osteoblast-related gene that is upregulat-
ed during differentiation and bone formation
(32) (see Fig. 1).
Previous analysis of the murine gene promoter identified two
RUNX2-specific enhancers (R1, R2) in the first 200 bp upstream
from the transcription start site that were both shown to be
necessary for osteoblast-specific expression.
(24) A third nonfunc-
tional RUNX2 consensus binding site also was identified at
–1300 bp (see schematic in Fig. 5A). This site did not bind RUNX2
in ChIP assays and was devoid of enhancer activity. To evaluate
the binding of P-ERK to Ibsp, MC3T3E1c4 cells were grown in GM
or DM for increasing times, and ChIP analysis was carried out
using specific primers flanking the R2 and R3 regions (see Fig. 5).
Note that because R1 and R2 are only separated by approxi-
mately 100 bp, the p7/p8 primer pair cannot discriminate
between binding to R1, R2, or both sites.
(24) Consistent with
results obtained with Bglap2, both RUNX2 and P-ERK bound to
the R1/R2 region, whereas neither factor interacted with R3. Also,
growth in DM clearly increased P-ERK binding after 3 or 6 days
without having any noticeable effect on RUNX2 (panel B). Lastly,
the differentiation-dependent increase in P-ERK binding seen on
day 6 was preferentially blocked with MAP kinase inhibition
without affecting RUNX2 (panel C). In summary, the specificity
and MAP kinase dependence of P-ERK interactions with Ibsp are
Fig. 5. Association of RUNX2 and P-ERK with Ibsp chromatin during osteoblast differentiation. (A) Schematic of the Ibsp proximal promoter regions
showing positions of PCR primers for ChIP analysis. The P7/P8 primer pair detects interactions with a proximal promoter region containing 2 RUNX2
binding sites, whereas P9/P10 detects interactions with a distal region devoid of in vivo RUNX2 interactions. (B) RUNX2 and P-ERK ChIP assays. Cells were
grown as in Fig. 2. Note differentiation-dependent increases in P-Erk binding to the proximal promoter regions. (C) MAP kinase dependence of P-ERK
binding.
160 Journal of Bone and Mineral Research LI ET AL.quite similar to those observed for Bglap2, making it highly likely
that we are observing a general phenomenon related to the
interaction of P-ERK with RUNX2 target genes.
Discussion
In this study we examined the subcellular distribution of P-ERK
during osteoblast differentiation and relate these changes to the
known ability of ERK-MAPK signals to induce bone-specific gene
expression. During differentiation, P-ERK accumulated in the
nucleus, where it specifically bound to the chromatin of Pglap2
and Ibsp genes near the RUNX2 transcription factor. P-ERK-
chromatin binding required intact RUNX2-specific enhancer
sequences in target genes, was detected only in RUNX2-
expressing cells, and could be blocked by pharmacologic
inhibitionofERK-MAPKsignaling.Asisclearlyshowninthiswork,
P-ERK does not have a random distribution in osteoblast nuclei.
Instead, it directly interacts with target genes to facilitate their
activation during differentiation.
Although previous studies established an important role for
ERK-MAPKsignalinginosteoblastdifferentiation,themechanism
of action of this pathway has not been explored extensively
beyond showing that MAPK can increase transcriptional activity
and phosphorylation of RUNX2.
(4,13,16,17) To gain further insight
into the role of MAPK signaling in osteoblast differentiation, we
examined the detailed subcellular distribution of P-ERK.
Undifferentiated MC3T3-E1c4 cells were found to contain low
levels of P-ERK. This P-ERK was barely detectable on
Western blots but was clearly visible by immunofluorescence
confocal microscopy, where it was seen mainly in the cytosol.
Interestingly, some of this cytosolic P-ERK was clustered in
perinuclear regions, especially at early time points. Although we
have not attempted to further localize this material, in other
systems, part of the cellular P-ERK pool is retained in the
cytoplasm in complex with the Golgi apparatus, where it
phosphorylates cytoplasmic targets.
(33) This cytoplasmic P-ERK
pool may be required to maintain certain cellular functions in
undifferentiatedcells.WhenMC3T3-E1c4cellsweregrownunder
differentiating conditions, we observed increases in both the
amount of P-ERK relative to the total ERK pool, as well as a clear
redistribution of P-ERK to the nucleus. In contrast, immunolo-
calization of the RUNX2 transcription factor revealed a similar
punctate nuclear distribution in control and differentiating cells
at all time points examined. Since P-ERK accumulated in the
nucleus during differentiation, clear colocalization with RUNX2
became apparent.
Our novel finding that at least a portion of the nuclear P-ERK
can be detected in complex with the chromatin of osteoblast-
related genes is of particular interest and may begin to explain
how MAP kinase can regulate gene expression. Both RUNX2 and
P-ERK selectively associated with known RUNX2 enhancer
regions of Bglap2 and Ibsp genes. Furthermore, P-ERK and, to
a lesser extent, RUNX2 binding was upregulated in differentiat-
ing cells at both day 3 and day 6 time points.
Surprisingly, growth in DM did not increase P-ERK binding to
either gene at the day 9 time point even though immuno-
fluorescence data revealed clear increases in nuclear P-ERK
under thiscondition. This result maybe explainedby increasesin
the heterogeneity of osteoblast cultures during differentiation.
Over time, cells form multilayered structures, with proliferating
cells remaining at the medium–cell layer interface and more
differentiated cells being incorporated into the collagenous
matrix, where they initiate mineralization within collagen
fibrils.
(34,35) An example of this heterogeneity is shown in
Fig. 2A. Although growth in DM clearly increased nuclear P-ERK,
this was apparent only in a fraction of the total cells in each field,
particularly at the later time points. Possibly, cells not containing
nuclear P-ERK are diluting the ChIP assay signal under this
condition.
We used a variety of approaches to establish the specificity of
P-ERK-chromatin interactions. Significantly, P-ERK did not have a
random distribution on either Bglap2 or Ibsp genes. Instead, it
associated only with regions near functional binding sites for
RUNX2. Thus P-ERK associated with OSE2a and OSE2b regions of
the in Bglap2 promoter but not with a 3’ distal sequence within
the transcribed region. Similarly, it bound near R1/R2 RUNX2
enhancers in the proximal Ibsp promoter but not to a cryptic
nonfunctional RUNX2 consensus site at –1300 bp. Furthermore,
mutation of RUNX2 binding sites (OSE2a, OSE2b) in the Bglap2
promoter prevented both P-ERK and RUNX2 from associating
with chromatin. Lastly, P-ERK was unable to associate with these
chromatin regions in RUNX2-negative C3H10T1/2 cells, but
binding could be restored with RUNX2 overexpression.
Our results with P-ERK and RUNX2 are reminiscent of previous
observations related to muscle regeneration. This process is
cooperatively induced by p38 MAPK and P13K/AKT pathways in
response to acute injury.
(18,36) In this case, the muscle-related
transcription factors MyoD and MEF2 recruit p38a/b kinases to
the promoters of muscle-related genes such as myogenin and
muscle creatine kinase. Subsequent p38-dependent phosphor-
ylation events are necessary for recruitment of the SWI/SNF
chromatin-remodeling complex. Through a separate pathway,
AKT promotes the association of MYOD with p300 and PCAF
acetyltransferases. The resulting changes in acetylation convert
the chromatin of myogenic genes into an open conformation
that is permissive for transcription.
Subsequent reports described the association of nuclear
kinases with chromatin in a number of other tissues. For
example, after exposure of pancreatic b-cells toelevated glucose
concentrations, P-ERK binds to promoter regions of several
glucose-inducible genes, including the insulin gene, where it
recruits accessory transcription factors, including NFAT, MafA,
and PDX-1.
(37) Also, activation of mouse mammary tumor virus
(MMTV) transcription by progesterone involves formation of a
complex containing the progesterone receptor, ERK and the ERK
substrate mitogen and stress-activated kinase 1 (MSK1), on the
MMTV promoter followed by increased histone H3 phosphor-
ylation, formation of a chromatin remodeling complex, and
increased transcription.
(38) Lastly, in cortical neurons stimulated
with nerve growth factors and cardiomyocytes, polyADP-ribose
polymerase 1 (PARP-1) was shown to recruit P-ERK to the
nucleus, leading to phosphorylation/activation of the ERK
substrateElk1,CBP/p300phosphorylation,andincreasedhistone
acetylation.
(39) Perhaps most interestingly, studies in yeast
indicate that kinase occupancy of specific chromatin sites may
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eucaryotes.
(19) In these studies, ChIP-ChIP analysis was used to
show that, after activation, the yeast homologues of p38, ERK-
MAPK, and PKA all become associated with the chromatin of
multiple target genes to globally alter patterns of gene
expression in response to osmotic stress, pheromones, or
glucose exposure. Based on these studies, it was proposed that
nuclear kinases generally may function by associating with
multiple chromatin sites to globally alter gene expression.
The extent to which these concepts are applicable to bone is
currentlyunknown.ThepredominantroleofMAPKonosteoblast
chromatin may be to phosphorylate RUNX2, or it may have
additional, more global functions. As noted earlier, there is some
precedent for the concept that tissue-specific transcription
factors including myoD, PPARg, and Sox9 are regulated by
MAPK-dependent phosphorylation,
(11,12,14) and as was shown by
this laboratory, the ERK-MAPK pathway does, in fact, stimulate
RUNX2 phosphorylation and transcriptional activity in osteo-
blasts.
(13) We recently identified specific serine residues in the
C-terminal proline/serine/threonine-rich domain of RUNX2 that
are phosphorylated by MAPK and necessary for MAPK respon-
siveness (C Ge, G Xiao, Y Li, and RT Franceschi, submitted for
publication). Furthermore, we were able to detect interactions
between RUNX2 and P-ERK by coimmunoprecipitation. This
latter results suggest that the association of P-ERK with RUNX2-
binding regions of Bglap2 and Ibsp genes may be explained by
direct binding of this kinase to RUNX2.
However, in addition to being a potential P-ERK substrate,
RUNX2 also may function to target nuclear kinases to specific
chromatin regions, where they can have broader effects on
chromatin structure and transcription. The concept that RUNX2
can serve as part of a nuclear scaffold to sequester specific factors
within the nucleus was first proposed by the Stein/Lian laboratory
largely based on studies showing that RUNX factors are
components of the nuclear matrix and can target SMAD proteins
to specific nuclear regions.
(29) As noted earlier, chromatin-
associated kinases can trigger multiple events, including recruit-
ment and phosphorylation of other transcription factors and
histones, activation of secondary nuclear kinases, and stimulation
of histone acetylation and changes in chromatin structure. It is
therefore conceivable that nuclear kinases have similarly complex
rolesduringosteoblastdifferentiation.IncreasesinhistoneH3and
H4 acetylation have been correlated previously with differentia-
tion in primary osteoblasts, although the possible involvement of
nuclear kinases in this process has not been addressed.
(40) In
preliminarly studies, we detected increases in histone H3 and H4
acetylation during differentiation of MC3T3-E1c4 cells and found
that these increases could be blocked with MAP kinase inhibition
(not depicted), suggesting that one of the functions of nuclear P-
ERK in osteoblasts may be to regulate acetylation.
Although only Pglap2 and Ibsp interactions were examined in
the present study, we think it likely that P-ERK and other nuclear
kinases are associated with additional genes necessary for
induction and maintenance of the osteoblast phenotype. The
differentiation of osteoblasts from mesenchymal precursors
requires both the induction of genes necessary for maintenance
of the osteoblast phenotype and suppression of genes
associated with other mesenchymal lineages. Such control
requires a coordinated mechanism to simultaneously regulate
transcriptional activity at multiple sites. By associating with
osteoblast-related genes, nuclear kinases are ideally positioned
to provide this type of global control. This is a plausible
mechanism given that many of the major signals affecting
osteoblast differentiation (i.e., hormones/growth factors, extra-
cellular matrix, or mechanical loading) use MAP kinase–related
pathways to convey information from the cell surface to the
nucleus. However, the extent to which these concepts can be
applied generally to bone will require analysis of kinase
interactions with other osteoblast-related genes and associated
transcription factors in the presence of different osteogenic
signals. This analysis will be critical for mapping the transcrip-
tional networks activated as bone responds to a range of
environmental cues.
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